AccuImage names new CEO
Robert Taylor has been appointed CEO of AccuImage, a South San Francisco, CA-based developer of 3-D and 4-D post-processing and connectivity software for PACS and other medical imaging applications. Taylor, previously COO of AccuImage, replaces Allen
Robert Taylor has been appointed CEO of AccuImage, a South San Francisco, CA-based developer of 3-D and 4-D post-processing and connectivity software for PACS and other medical imaging applications. Taylor, previously COO of AccuImage, replaces Allen Poirson, who resigned from the company.
AccuImage expects Taylors appointment to help expedite AccuImages current product development efforts, which include AccuView, a 3-D workstation, and eStation 3D, a Web-based workstation for PACS and teleradiology. Taylor will be responsible for moving AccuView into the marketplace and overseeing final development of eStation 3D, according to Douglas Boyd, chairman of AccuImage. Both products incorporate AccuImages proprietary software platform, which provides review and analysis tools for CT, MR, and ultrasound imaging and enables the transfer of medical images across the Internet and hospital intranets.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
